A recent phase III trial showed better survival with additional LAT, indicating that LAT could be considered for the treatment of synchronous oligometastatic disease in patients with EGFR-mutated NSCLC [30,34]. The gene discussed is LAT; the disease is non-small cell lung carcinoma.